Shares of cybersecurity company CrowdStrike (CRWD.US) lose today almost 7% despite strong quarter, as cybersecurity provider missed Q4 2024 guidance. A software update in July caused widespread disruptions across industries, leading to lawsuits, including a $500 million claim by Delta Air Lines. Despite that, CEO George Kurtz remains optimistic, emphasizing ability to recover and accelerate ARR growth by 2026. Investors expect that Falcon platform and new Next-Gen SIEM offering will drive future growth.
- EPS: Adjusted earnings of $0.93 per share (beating estimates of $0.81).
- Revenue: $1.01 billion, a 29% increase year-over-year.
- Annual Recurring Revenue (ARR): Surpassed $4 billion, showcasing sustained momentum in its subscription-based model.
- Guidance miss: Expected Q4 EPS of $0.84-$0.86 fell slightly below analyst expectation of $0.87
The more cautious outlook has raised investor concerns about CrowdStrike's recovery from a significant software update failure in July, which disrupted millions of Microsoft Windows machines across various sectors, including air travel, banking, and healthcare. TD Cowen reiterated a $380 price target, citing the Q3 dip as a short-term setback rather than a long-term derailment.
CrowdStrike (D1 interval)
On a D1 stock chart, we can see a potential bearish head and shoulders pattern. Falling below EMA50 and EMA200 would be also confirmation of a potential bearish flag technical formation.
Source: xStation5
Tesla falls 1.30% despite record quarterly revenue 🔎
Daily wrap – US Export Restrictions on China and Weaker Earnings Trigger Wall Street Correction
Google Quantum Echoes – A Quantum Computing Breakthrough
Those Stocks Scared Investors Ahead Of This Halloween🎃 — Market Losers of 2025
The material on this page does not constitute as financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other particular needs.
All the information provided, including opinions, market research, mathematical results and technical analyses published on the website or transmitted to you by other means is provided for information purposes only and should in no event be interpreted as an offer of, or solicitation for, a transaction in any financial instrument, nor should the information provided be construed as advice of legal or fiscal nature.
Any investment decisions you make shall be based exclusively on your level of understanding, investment objectives, financial situation or any other particular needs. Any decision to act on information published on the website or transmitted to you by other means is entirely at your own risk. You are solely responsible for such decisions.
If you are in doubt or are not sure that you understand a particular product, instrument, service, or transaction, you should seek professional or legal advice before trading.
Investing in OTC Derivatives carries a high degree of risk, as they are leveraged based products and often small movements in the market could lead to much larger movements in the value of your investment and this could work against you or for you. Please ensure that you fully understand the risks involved, taking into account your investments objectives and level of experience, before trading, and if necessary, seek independent advice.
